Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
复制标题
DOI：
10.1111/j.1464-410x.2008.07501.x
复制
发表时间：
2008-04-01
影响因子：
4.5
通讯作者：
Nadler, Robert B.
中科院分区：
文献类型：
--
作者：
Loeb, Stacy;Roehl, Kimberly A.;Nadler, Robert B.
前列腺特异性抗原速度（PSAV），以确定是否是有用的前列腺癌检测男性从不同年龄组，以及是否相同的PSAV阈值可以合理地适用于所有男性年龄>= 40 years.PATIENTS AND METHODS从一个大型前列腺癌筛查研究，13 615名男性的年龄和可计算的PSAV的数据。我们使用统计分析来检验PSAV预测每个年龄段前列腺癌风险的能力。对于所有年龄段的男性，前列腺癌男性的中位PSAV为0.6-0.7 ng/mL/年，而非前列腺癌男性的中位PSAV为0-0.1 ng/mL/年（P < 0.005）。在受试者工作特征（ROC）分析中，使用PSAV预测40-49岁、50-59岁、60-69岁和≥ 70岁男性前列腺癌风险的曲线下面积分别为0.800、0.697、0.693和0.668。在多变量模型控制种族，家族史，总PSA水平，PSA和PSAV是显着的独立预测前列腺癌的风险在所有年龄段的男性。CONCLUSIONSThe PSAV是显着较高的所有年龄段的男性前列腺癌与男性相比，没有前列腺癌，虽然在ROC分析，它表现最好的年轻男性。有趣的是，前列腺癌男性的中位PSAV < 0.75 ng/mL/年，与年龄无关，这表明该阈值可能过高。总体而言，该数据证实PSAV是年龄≥ 40岁男性前列腺癌检测的有用工具。
OBJECTIVETo determine whether prostate-specific antigen velocity (PSAV) is useful for prostate cancer detection in men from different age groups, and whether the same PSAV thresholds can reasonably be applied to all men aged >= 40 years.PATIENTS AND METHODSFrom a large prostate cancer screening study, 13 615 men had data on age and a calculable PSAV. We used statistical analysis to examine the ability of PSAV to predict prostate cancer risk in each age decade.RESULTSFor men of all ages, the median PSAV was 0.6-0.7 ng/mL/year in men with prostate cancer, and 0-0.1 ng/mL/year in men with no prostate cancer (P < 0.005 for all). On receiver operating characteristic (ROC) analysis, the area under the curve was 0.800, 0.697, 0.693, and 0.668 for predicting prostate cancer risk using PSAV for men aged 40-49, 50-59, 60-69 and >= 70 years, respectively. In the multivariate model controlling for race, family history, and the total PSA level, both PSA and PSAV were significant independent predictors of prostate cancer risk in men of all ages.CONCLUSIONSThe PSAV is significantly higher in men of all ages with prostate cancer compared with men with no prostate cancer; although on ROC analysis it performed the best in young men. Interestingly, the median PSAV in men with prostate cancer was < 0.75 ng/mL/year regardless of age, suggesting that this threshold may be too high. Overall, this data confirms that PSAV is a useful tool for prostate cancer detection for men aged >= 40 years.